6533b854fe1ef96bd12af49f
RESEARCH PRODUCT
Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure
Antonin SchmittLeila Bengrine-lefevreJulie VincentFrançois GhiringhelliBernard RoyerFrançoise GoirandMarine DolatRémi PalmierAudrey HennequinPauline Macairesubject
0301 basic medicinemedicine.medical_specialtyUH2/U ratioFOLFIRINOXtherapeutic drug monitoringuracilemiaPharmaceutical Sciencelcsh:Medicinelcsh:RS1-441GastroenterologyArticlelcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicinePharmacokineticsInternal medicineDrug DiscoveryDihydropyrimidine dehydrogenaseMedicine5-FUmedicine.diagnostic_testbusiness.industrylcsh:RDPDmedicine.diseasePrimary tumorGI cancer030104 developmental biologyDocetaxelTherapeutic drug monitoring030220 oncology & carcinogenesisToxicityUH<sub>2</sub>/U ratioMolecular MedicineDPYDbusinesspharmacokineticsmedicine.drugdescription
In order to limit 5-fluorouracil (5-FU) toxicity, some health agencies recommend evaluating dihydropyrimidine dehydrogenase (DPD) deficiency before any 5-FU treatment introduction. In our study, we investigated relationships between 5-FU clearance and markers of DPD activity such as uracilemia (U), dihydrouracilemia (UH2)/U ratio, or genotype of the gene encoding DPD (DPYD). All patients with gastrointestinal cancers who received 5-FU-based regimens form March 2018 to June 2020 were included in our study. They routinely benefited of a pre-therapeutic DPYD genotyping and phenotyping. During 5-FU infusion, blood samples were collected to measure 5-FU steady-state concentration in order to adapt 5-FU doses at the following cycles. A total of 169 patients were included. Median age was 68 (40&ndash
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-11-23 | Pharmaceuticals |